Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations
- 24 August 2022
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 28 (14) , 2177-2189
Abstract
Background: As patents for multiple sclerosis (MS) therapies expire, follow-on disease-modifying treatments (FO-DMTs) become available at reduced cost. Concerns exist that cheaper FO-DMTs are used simply to reduce healthcare costs. However, the well-being of people with MS should take priority. Objectives: To identify best practices for FO-DMT development and use by agreeing on principles and consensus statements through appraisal of published evidence. Methods: Following a systematic review, we formulated five overarching principles and 13 consensus statements. Principles and statements were voted on by a multidisciplinary panel from 17 European countries, Argentina, Canada and the United States. Results: All principles and statements were endorsed by >80% of panellists. In brief, FO-DMTs approved within highly regulated areas can be considered effective and safe as their reference products; FO-DMTs can be evaluated case by case and do not always require Phase III trials; long-term pharmacovigilance and transparency are needed; there is lack of evidence for multiple- and cross-switching among FO-DMTs; and education is needed to address remaining concerns. Conclusion: Published data support the use of FO-DMTs in MS. The consensus may aid shared decision-making. While our consensus focused on Europe, the results may contribute to enhanced quality standards for FO-DMTs use elsewhere.Keywords
Funding Information
- Synthon
- Gerot Lannach
- Viatris
This publication has 38 references indexed in Scilit:
- Switching from branded to generic glatiramer acetate: 15-month GATE trial extension resultsMultiple Sclerosis Journal, 2017
- ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An UpdateJournal of Crohn's and Colitis, 2016
- Experience in the Use of the β-Interferon-1a Biosimilars CinnoVex and Genfaxon-44 at the Moscow City Multiple Sclerosis CenterNeuroscience and Behavioral Physiology, 2016
- The regulator’s perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?Multiple Sclerosis Journal, 2016
- Patient attitudes and understanding about biosimilars: an international cross-sectional surveyPatient Preference and Adherence, 2016
- Equivalence of Generic Glatiramer Acetate in Multiple SclerosisJAMA Neurology, 2015
- Demonstration of equivalence of a generic glatiramer acetate (Glatopa™)Journal of the Neurological Sciences, 2015
- Biosimilars in rheumatology: what the clinician should knowRMD Open, 2015
- Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug AdministrationAnnals of Pharmacotherapy, 2009
- An Experimental Application of the DELPHI Method to the Use of ExpertsManagement Science, 1963